Results 81 to 90 of about 46,971 (258)

Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?

Vaccines, 2019
Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal,
Ezra Linley, Abigail Bell, Jenna F. Gritzfeld, Ray Borrow   +3 more
doaj   +1 more source

Etiology of Acute Otitis Media and Characterization of Pneumococcal Isolates After Introduction of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Children

The Pediatric Infectious Disease Journal, 2018
Background: Acute otitis media is a leading cause of childhood morbidity and antibiotic prescriptions. We examined etiologic changes in acute otitis media after introduction of 13-valent pneumococcal conjugate vaccine as routine immunization for Japanese
K. Ubukata, Miyuki Morozumi, Megumi Sakuma, Misako Takata, E. Mokuno, T. Tajima, S. Iwata   +6 more
semanticscholar   +1 more source

TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.

JCI Insight, 2017
Infection is the most common cause of mortality in early life, and immunization is the most promising biomedical intervention to reduce this burden. However, newborns fail to respond optimally to most vaccines.
David J. Dowling, S. V. van Haren, A. Scheid, Ilana Bergelson, Dhohyung Kim, Christy J Mancuso, W. Foppen, A. Ozonoff, L. Fresh, Terese B Theriot, A. Lackner, R. Fichorova, D. Smirnov, J. Vasilakos, Joe M Beaurline, M. Tomai, C. Midkiff, X. Alvarez, J. Blanchard, Margaret H. Gilbert, P. Aye, O. Levy   +21 more
semanticscholar   +1 more source

In‐Hospital Mortality and Severe Respiratory and Renal Outcomes—A Territory‐Wide Comparison Between RSV and Influenza

Influenza and Other Respiratory Viruses, Volume 19, Issue 6, June 2025.
ABSTRACT Introduction Respiratory syncytial virus (RSV) and influenza virus are important respiratory viruses. Although RSV vaccines have been developed and recommended for patients aged ≥ 60, there is limited data on the clinical impact among the non‐elderly population.
Wang Chun Kwok, Isaac Sze Him Leung, James Chung Man Ho, Chung Ki Tsui, David Chi Leung Lam, Mary Sau Man Ip, Kelvin Kai Wang To, Desmond Yat Hin Yap   +7 more
wiley   +1 more source

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

PLoS ONE, 2017
Background The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine.
Á. Domínguez, P. Ciruela, S. Hernández, J. García-García, N. Soldevila, C. Izquierdo, F. Moraga-Llop, A. Díaz, Mariona F. de Sevilla, S. González-Peris, M. Campins, S. Uriona, J. Martínez-Osorio, A. Solé-Ribalta, G. Codina, C. Esteva, A. Planes, C. Muñoz-Almagro, L. Salleras   +18 more
semanticscholar   +1 more source

Uptake of Pneumococcal Vaccines Among U.S. Adults After 2022 Update to Recommendations

AJPM Focus
Introduction: Updated recommendations for adult pneumococcal vaccination in the U.S. (publication date: January 27, 2022) incorporated 2 new vaccines (15- and 20-valent pneumococcal conjugate vaccines), removed 13-valent pneumococcal conjugate vaccine ...
Ahuva Averin, MPP, Jeffrey Vietri, PhD, Adriano Arguedas Mohs, MD, Sarah J. Willis, PhD, MPH, Alexander Lonshteyn, PhD, Derek Weycker, PhD   +5 more
doaj  

Effectiveness of Pneumococcal Polysaccharide Vaccine for Preschool-Age Children with Chronic Disease

Emerging Infectious Diseases, 1999
To estimate the effectiveness of pneumococcal polysaccharide vaccine, we serotyped isolates submitted to the Pneumococcal Sentinel Surveillance System from 1984 to 1996 from 48 vaccinated and 125 unvaccinated children 2 to 5 years of age.
Anthony E. Fiore, Orin S. Levine, John A. Elliott, Richard R. Facklam, Jay C. Butler   +4 more
doaj   +1 more source

Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France

Open Forum Infectious Diseases, 2016
Implementation of 13-valent conjugate pneumococcal vaccine in France has led to an overall antibiotic resistance decrease among invasive pneumococcal isolates.
C. Janoir, A. Lepoutre, L. Gutmann, E. Varon   +3 more
semanticscholar   +1 more source

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).

Vaccine, 2021
H. Platt, Jose Cardona, M. Haranaka, H. Schwartz, Sílvia Narejos Pérez, A. Dowell, Chih-Jen Chang, R. Dagan, G. Tamms, T. Sterling, L. Morgan, Yaru Shi, Alison Pedley, L. Musey, U. Buchwald   +14 more
semanticscholar   +1 more source

An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana

BMC Infectious Diseases, 2016
BackgroundAn outbreak of pneumococcal meningitis among non-infant children and adults occurred in the Brong-Ahafo region of Ghana between December 2015 and April 2016 despite the recent nationwide implementation of a vaccination programme for infants ...
B. Kwambana-Adams, F. Asiedu-Bekoe, B. Sarkodie, O. K. Afreh, G. K. Kuma, G. Owusu-Okyere, E. Foster-Nyarko, S. Ohene, Charles Okot, A. Worwui, C. Okoi, Madikay Senghore, Jacob K Otu, Chinelo Ebruke, R. Bannerman, K. Amponsa-Achiano, D. Opare, Gemma L. Kay, Timothy S Letsa, O. Kaluwa, E. Appiah-Denkyira, V. Bampoe, Syed M. A. Zaman, M. Pallen, U. d’Alessandro, J. Mwenda, M. Antonio   +26 more
semanticscholar   +1 more source